Business ❯ Pharmaceuticals ❯ Mergers and Acquisitions ❯ Bidding Wars

Avadel Pharmaceuticals

Lundbeck Challenges Alkermes With Up to $23-Per-Share Offer for Avadel

Analysts say the richer bid pressures Alkermes to decide its next move.